Adverum Biotechnologies, INC Form 4 insider transactions

Adverum Biotechnologies CEO Laurent Fischer reports significant changes in beneficial ownership following the company's acquisition by Eli Lilly and Company, involving cash and contingent value rights.

Adverum Biotechnologies' COO, Peter Soparkar, reported the disposition of common stock, RSUs, PSUs, and stock options following the company's acquisition by Eli Lilly and Company.

Adverum Biotechnologies, Inc. has completed its merger with Eli Lilly and Company, with shareholders receiving cash and contingent value rights.

Adverum Biotechnologies' Chief Development Officer reports changes in beneficial ownership following the company's acquisition by Eli Lilly and Company, converting shares, RSUs, PSUs, and options into cash and contingent value rights.

Adverum Biotechnologies' CFO, Linda M. Rubinstein, reported significant stock and option transactions following the company's acquisition by Eli Lilly and Company, effective December 9, 2025.

Adverum Biotechnologies Director Soo Hong's stock options were cancelled following the company's merger with Eli Lilly and Company's subsidiary, Flying Tigers Acquisition Corporation.

Adverum Biotechnologies director Scott M Whitcup's stock options were cancelled following the acquisition by Eli Lilly and Company, with some receiving cash and CVRs, and others cancelled for no consideration.

Adverum Biotechnologies, Inc. became a wholly-owned subsidiary of Eli Lilly and Company following a tender offer and merger, with shareholders receiving cash and contingent value rights.

Adverum Biotechnologies director Dawn Svoronos reported changes in beneficial ownership following the company's acquisition by Eli Lilly and Company, effective December 9, 2025.

Adverum Biotechnologies director James Paul Scopa reported the disposition of all common stock and stock options following the company's merger with Eli Lilly and Company.

Adverum Biotechnologies director C. David Nicholson's stock options were cancelled following the company's acquisition by Eli Lilly and Company, effective December 9, 2025.

Adverum Biotechnologies director Mark L. Lupher, Jr. disposed of all common stock and stock options following the company's acquisition by Eli Lilly and Company.

Adverum Biotechnologies director Patrick Machado disposed of all common stock and stock options following the company's acquisition by Eli Lilly and Company.

A director of Adverum Biotechnologies reported the cancellation and cash-out of stock options following the company's acquisition by Eli Lilly and Company.

Frazier Life Sciences Public Fund, L.P. disposed of its entire stake in Adverum Biotechnologies, Inc. following the completion of its merger with Eli Lilly and Company's subsidiary.

Adverum Biotechnologies' CEO and President, Laurent Fischer, acquired a substantial number of common shares in open market transactions in early December 2025.

Adverum Biotechnologies' Chief Operating Officer, Peter Soparkar, acquired 50,000 shares of common stock at a weighted-average price of $4.22 per share.

Adverum Biotechnologies' Director and 10% owner, Braden Michael Leonard, sold over 524,000 shares of common stock for approximately $2.2 million.

Adverum Biotechnologies Director and 10% owner Braden M. Leonard sold 574,886 shares of common stock for approximately $2.4 million across three transactions in early December 2025.

Adverum Biotechnologies' Chief Operating Officer, Peter Soparkar, has had a significant portion of his stock options repriced to an exercise price of $10.14 per share, following a 1-for-10 reverse stock split.

Adverum Biotechnologies, Inc.'s Chief Development Officer, Setareh Seyedkazemi, had several stock options repriced to an exercise price of $10.14 per share following the company's recent 1-for-10 reverse stock split.

Adverum Biotechnologies, Inc.'s Chief Financial Officer, Linda M. Rubinstein, had her stock options amended and repriced to a lower exercise price following the company's 1-for-10 reverse stock split.

Adverum Biotechnologies' Chief Medical Officer, Rabia Gurses Ozden, amended two sets of stock options, resulting in a lower exercise price of $10.14 per share following the company's 1-for-10 reverse stock split.

Adverum Biotechnologies, Inc. CEO, President, and Director Laurent Fischer has repriced 564,418 stock options, significantly lowering their exercise prices to $10.14 per share following a reverse stock split.

Adverum Biotechnologies, Inc. Director Szilard Kiss was granted 10,450 stock options with an exercise price of $2.32, vesting on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders.

Adverum Biotechnologies, Inc. Director James Paul Scopa was granted 10,450 stock options with an exercise price of $2.32, vesting on June 17, 2026, or the 2026 annual meeting.

Adverum Biotechnologies, Inc. Director Scott M. Whitcup was granted 10,450 stock options with an exercise price of $2.32, vesting on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders.

Adverum Biotechnologies, Inc. Director Reed Vaughn Tuckson was granted 10,450 stock options with an exercise price of $2.32, vesting on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders.

Adverum Biotechnologies, Inc. director Dawn Svoronos was granted 10,450 stock options with an exercise price of $2.32, vesting by June 2026.

Adverum Biotechnologies, Inc. Director Mark L. Lupher, Jr. was granted 10,450 stock options with an exercise price of $2.32, vesting by June 2026.